Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450534 | 0.92 | ALDH1A1 (0.60) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL449318 | 0.89 | HTR7 (0.54) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL451679 | 0.84 | ALDH1A1 (0.52) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL454025 | 0.83 | ALDH1A1 (0.60) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL452102 | 0.83 | ALDH1A1 (0.58) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL451951 | 0.80 | HTR7 (0.53) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL450438 | 0.80 | ALDH1A1 (0.67) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL452387 | 0.79 | HTR7 (0.59) | HTR7ALDH1A1SMN1; SMN2RAB9AACKR3 | |
| SCHEMBL449747 | 0.79 | HTR7 (0.55) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL1554547 | 0.77 | ALDH1A1 (0.63) | HTR7ALDH1A1MAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | HTR7 1136/4885ALDH1A1 3161/4885MAPT 4075/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | HTR7 1136/4885ALDH1A1 3161/4885MAPT 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.